Teivelis Marcelo Passos, Wolosker Nelson, Krutman Mariana, Kauffman Paulo, Campos José Ribas Milanez de, Puech-Leão Pedro
Hospital Israelita Albert Einstein, Vascular Surgery, São Paulo, SP, Brazil.
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HC/FMUSP), Thoracic Surgery Division, São Paulo, SP, Brazil.
Clinics (Sao Paulo). 2014 Sep;69(9):608-14. doi: 10.6061/clinics/2014(09)06.
Primary hyperhidrosis usually affects the hands, armpits, feet and cranio-facial region. Sweating in other areas is common in secondary hyperhidrosis (after surgery or in specific clinical conditions). Oxybutynin has provided good results and is an alternative for treating hyperhidrosis at common sites. Our aim was to evaluate the efficacy of oxybutynin as a treatment for primary sweating at uncommon sites (e.g., the back and groin).
This retrospective study analyzed 20 patients (10 females) who received oxybutynin for primary focal hyperhidrosis at uncommon sites. The subjects were evaluated to determine quality of life before beginning oxybutynin and six weeks afterward and they were assigned grades (on a scale from 0 to 10) to measure their improvement at each site of excessive sweating after six weeks and at the last consult.
The median follow-up time with oxybutynin was 385 days (133-1526 days). The most common sites were the back (n = 7) and groin (n = 5). After six weeks, the quality of life improved in 85% of the subjects. Dry mouth was very common and was reported by 16 patients, 12 of whom reported moderate/severe dry mouth. Five patients stopped treatment (two: unbearable dry mouth, two: excessive somnolence and one: palpitations). At the last visit, 80% of patients presented with moderate/great improvement at the main sites of sweating.
After six weeks, more than 80% of the patients presented with improvements in their overall quality of life and at the most important site of sweating. Side effects were common (80% reported at least one side effect) and caused 25% of the patients to discontinue treatment. Oxybutynin is effective for treating bothersome hyperhidrosis, even at atypical locations and most patients cope well with the side effects.
原发性多汗症通常影响手部、腋窝、足部和颅面部区域。在继发性多汗症(手术后或特定临床情况下),身体其他部位出汗很常见。奥昔布宁已取得良好效果,是治疗常见部位多汗症的一种选择。我们的目的是评估奥昔布宁治疗不常见部位(如背部和腹股沟)原发性出汗的疗效。
这项回顾性研究分析了20例接受奥昔布宁治疗不常见部位原发性局灶性多汗症的患者(10名女性)。在开始使用奥昔布宁前和六周后对受试者进行生活质量评估,并为他们打分(0至10分),以衡量六周后及最后一次复诊时每个多汗部位的改善情况。
使用奥昔布宁的中位随访时间为385天(133 - 1526天)。最常见的部位是背部(n = 7)和腹股沟(n = 5)。六周后,85%的受试者生活质量得到改善。口干非常常见,16例患者报告有此症状,其中12例报告为中度/重度口干。5例患者停止治疗(2例:无法忍受的口干,2例:过度嗜睡,1例:心悸)。在最后一次就诊时,80%的患者在主要出汗部位有中度/显著改善。
六周后,超过80%的患者整体生活质量及最重要的出汗部位有改善。副作用很常见(80%的患者报告至少有一种副作用),导致25%的患者停药。奥昔布宁对治疗令人烦恼的多汗症有效,即使在非典型部位,且大多数患者能较好地应对副作用。